On October 21, Academician Tang Xican of the Chinese Academy of Engineering came to Wanbangde Pharmaceutical to inspect and guide the work and had a discussion and exchange, accompanied by relevant personnel of Wenling Association for Science and Technology.

Academician Tang Xican went deep into the workshop to inspect the production of products, and listened carefully to the key technologies and processes of drug production and quality management and the construction plan of the new industrialization support platform in the future. The ability to add value and other aspects has been highly evaluated.

Academician Tang Xican inspected the product production line

Academician Tang Xican communicated with Chen An, executive deputy general manager of Wanbangde Pharmaceutical, on the production process of products

       At the symposium, Chen An, executive deputy general manager of Wanbangde Pharmaceutical, humbly asked Academician Tang for advice on the difficulties and problems encountered in the in-depth development of the Huperzine A project. After repeated communication, Academician Tang put forward valuable opinions and suggestions on the problems arising in the project research process. In addition, Academician Tang also said: "In the 1980s, we were in step with the world in the research and development of drugs for the treatment of Alzheimer's disease. In addition to slowing down Alzheimer's disease, Huperzine A It has a great effect on benign memory disorders. We cooperated with Wanbangde Pharmaceutical to research and develop Huperzine A, hoping to further expand the scope of indications of this product injection and improve the product quality to a new level. The Huperzine A controlled-release tablet researched and developed has also successfully entered the first phase of clinical trials. If all goes well, we will enter the next phase of research as soon as possible, and bring the product to the market as soon as possible, benefiting the majority of patients.”

Academician Tang Xican and Executive Vice President Chen An conducted a project discussion

Chen An, the executive deputy general manager of Wanbangde Pharmaceutical, introduced that the company is currently cooperating with the academician team to develop a sustained and controlled release formulation of Huperzine A. The patient has changed from twice a day to once, and the patient's compliance is better. He pointed out that due to the dose relationship, high doses will have a greater impact on peripheral cholinergic, and the side effects on the gastrointestinal tract are more prominent. Make corresponding adjustments to reduce the occurrence of side effects of patients and improve the efficacy of drugs.

It is understood that since Wanbangde Pharmaceutical and Academician Tang Xican reached a cooperative relationship and established the "Academician Expert Workstation" in 2015, the two parties have carried out in-depth cooperation on the Huperzine A project, integrated the advantageous resources of both parties, and gave full play to the advantages of both parties. With the support of the technical force of the team, the preparations of Huperzine A have achieved certain results so far. Huperzine A injection has been mass-produced and sold; Huperzine A controlled-release tablets have entered the first phase of clinical trials. It is believed that these varieties will bring more economic benefits to the enterprise.